Bausch + Lomb Corporation

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 02:18:00 2026-01-21 pm EST			5-day change	1st Jan Change
17.26 ^USD	+0.97%		-0.32%	+1.08%

Jan. 13	Bausch Health Brief: Co Provides Filing Ahead of Participating in 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026	MT
Jan. 13	Bausch Health Brief: Management Expects to Reaffirm FY25 Guidance at Higher End of Range for Itself Excluding Bausch + Lomb As Provided In October	MT

Bausch + Lomb Shares Rise After Citigroup Upgrade

Published on 12/11/2025 at 03:16 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bausch + Lomb Corporation

Jan. 13	Bausch Health Brief: Co Provides Filing Ahead of Participating in 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026	MT
Jan. 13	Bausch Health Brief: Management Expects to Reaffirm FY25 Guidance at Higher End of Range for Itself Excluding Bausch + Lomb As Provided In October	MT
Jan. 12	Bausch + Lomb Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
Jan. 02	Bausch + Lomb Refinances Outstanding Term B Loans	MT
Jan. 02	Bausch + Lomb Completes Refinancing of Outstanding Term B Loans	MT
Jan. 02	Bausch + Lomb Completes Refinancing of Outstanding Term B Loans	CI
Dec. 17	Bausch + Lomb Brief: Appointing Eduardo C. Alfonso, and Steven H. Collis To Its Board, Effective Jan. 1, 2026; Board Will Then Be Comprised of 10 Directors	MT
Dec. 17	Bausch + Lomb Corporation Announces Board Appointments, Effective January 1, 2026	CI
Dec. 12	Bausch + Lomb Refinancing Outstanding Term B Loans	MT
Dec. 12	Bausch + Lomb Brief: Announcing Refinancing of Outstanding Term B Loans	MT
Dec. 12	Bausch + Lomb Announces Refinancing of Outstanding Term B Loans	CI
Dec. 11	Bausch + Lomb Shares Rise After Citigroup Upgrade	MT
Dec. 11	Citigroup Upgrades Bausch + Lomb to Buy From Neutral, Adjusts Price Target to $20 From $16	MT
Dec. 03	Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 09:00 AM
Dec. 02	Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	MT
Dec. 02	Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equal Weight, Adjusts PT to CA$29.41 From CA$19.64	MT
Nov. 17	Bausch + Lomb Corporation - Analyst/Investor Day
Nov. 14	RBC Raises Price Target on Bausch + Lomb to $19 From $17, Keeps Outperform Rating	MT
Nov. 13	Bausch + Lomb Targets Above-Market Growth, Double-Digit EPS Gains Through 2028	MT
Nov. 13	Bausch + Lomb Seeks Acquisitions	CI
Nov. 13	Bausch + Lomb Brief: Will Also Feaffirm its 2025 Guidance	MT
Nov. 13	Bausch + Lomb Brief: Will Unveil Plans to Achieve "Above-market revenue growth and meaningful margin expansion"	MT
Nov. 13	Bausch + Lomb Brief: Said To Highlight Company "Transformation And Growth Strategy" At Investor Day Today	MT
Nov. 10	Bausch + Lomb Brief: Reporting More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program	MT
Nov. 05	Needham Maintains Hold on Bausch + Lomb Ahead of Investor Day	MT

Chart Bausch + Lomb Corporation

Duration

Period

BLCO: Dynamic Chart

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Employees

13,500

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 17 - Q4 2025 Earnings Release

More about the company